PUBLISHER: Acute Market Reports | PRODUCT CODE: 1192903
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1192903
Tardive Dyskinesia (TD) Treatment Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
Tardive dyskinesia (TD) is rare neurological disorder due to long term use of antipsychotic medications which act on dopamine receptors. It is anticipated that the TD treatment drugs market will show significant market growth over the forecast period owing to some factors such as increasing prevalence of TD, higher number of unmet needs for treatment of TD and expected launch of pipeline drug. Although there are various drugs used in treatment of TD, presently only Valbenazine and Deutetrabenazine are approved by the FDA. Other drugs such as benzodiazepines, botulinum toxin, amantadine, dopamine-depleting agents and calcium channel blockers etc. are also used in symptomatic relief from TD.
The report titled "Tardive dyskinesia (TD) Treatment Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030" includes in-depth analysis of TD treatment drugs market for period from 2020 to 2030. For the detailed market study, TD treatment drugs market is categorized on the basis of drug types: Valbenazine, Deutetrabenazine and other drugs (benzodiazepines, botulinum toxin, vitamin E, amantadine, levodopa, reserpine, dopamine-depleting agents and calcium channel blockers etc.)
With a view to present in-depth geographical study, the global TD treatment drugs market is segmented on the basis of key regional markets such as North America, Europe, Latin America, Asia Pacific and Middle East and Africa. For country level analysis, TD treatment drugs market is segmented into Canada, United States, United Kingdom, Germany, rest of Europe, Mexico, Brazil, Rest of Latin America, China, Japan, rest of Asia Pacific, GCC and rest of Middle East and Africa.
This report covers detailed study of qualitative information along with statistical data for better understanding of the current market situation and future market scenario. For better understanding about the ongoing market trends and future market prospects, in-depth information about the market drivers, opportunities and challenges of global TD treatment drugs market are covered in report. Attractive investment propositions and company profiling section provide detail information about the key players involved in global TD treatment drugs market.
Tardive dyskinesia is a neurological movement disorder occurring due to long term use of neuroleptics or anti-psychotic medications. It is considered as a rare disorder as it affects less than 200,000 people in the United States alone. Treatment of TD is highly individualized and the first step is to minimize the use of neuroleptic drugs. Different forms of drugs are used in reducing the symptoms of TD, but only two drugs Valbenazine (Neurocrine Biosciences, Inc.) and deudeutetrabenazine (Teva Pharmaceutical Industries Ltd.) are approved by the US-FDA exclusively for the treatment of TD. It is estimated that Valbenazine and Deutetrabenazine will show significant market growth over the forecast period due to their clinically proven efficacy and target specificity. Other drugs such as benzodiazepines, botulinum toxin, vitamin E, amantadine, levodopa, reserpine, dopamine-depleting agents and calcium channel blockers etc. are also used to reduce symptoms of TD. Prominent pipeline drugs such as SNC-102 (Synchroneuron) expected to assist market growth during the forecast period 2022- 2030.
Tardive dyskinesia is an antipsychotic drug induced movement disorder characterized by evident abnormal involuntary movements. Among the considered geographical markets, North America is the major revenue contributing region in global TD treatment drugs market. Key factors facilitating the dominance of North America are early diagnosis, wide accessibility to treatment drugs, greater number of affected population and well developed healthcare infrastructure. Studies have indicated that more than 50,000 patients are affected with TD in the United States. Ideal pipeline drug (SNC-102) and recent approvals to Valbenazine and Deutetrabenazine are expected to drive significant market growth in North America. TD treatment drugs market in Asia Pacific is set to capture significant position on account of rising treatment awareness among the general population, growing number of affected population and developing healthcare infrastructure.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Tardive Dyskinesia (TD) Treatment Drugs market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Tardive Dyskinesia (TD) Treatment Drugs market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Drug
Valbenazine
Deutetrabenazine
Other
Region Segment (2020-2030; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Global Impact of COVID-19 Segment (2020-2021; US$ Million )
Pre COVID-19 situation
Post COVID-19 situation
Key questions answered in this report:
What are the key micro and macro environmental factors that are impacting the growth of Tardive Dyskinesia (TD) Treatment Drugs market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2030.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Tardive Dyskinesia (TD) Treatment Drugs market?
Which is the largest regional market for Tardive Dyskinesia (TD) Treatment Drugs market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Tardive Dyskinesia (TD) Treatment Drugs market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Tardive Dyskinesia (TD) Treatment Drugs market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Tardive Dyskinesia (TD) Treatment Drugs Market
- 2.2. Global Tardive Dyskinesia (TD) Treatment Drugs Market, By Drug, 2021 (US$ Million)
- 2.3. Global Tardive Dyskinesia (TD) Treatment Drugs Market, By Geography, 2021 (US$ Million)
- 2.4. Attractive Investment Proposition by Geography, 2021
3. Tardive Dyskinesia (TD) Treatment Drugs Market: Competitive Analysis
- 3.1. Market Positioning of Key Tardive Dyskinesia (TD) Treatment Drugs Market Vendors
- 3.2. Strategies Adopted by Tardive Dyskinesia (TD) Treatment Drugs Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2021 Versus 2030
4. Tardive Dyskinesia (TD) Treatment Drugs Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Tardive Dyskinesia (TD) Treatment Drugs Market Value, 2020 - 2030, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
5. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2021 Versus 2030
- 5.3. Market Segmentation
- 5.3.1. Valbenazine
- 5.3.2. Deutetrabenazine
- 5.3.3. Other
6. North America Tardive Dyskinesia (TD) Treatment Drugs Market, 2020-2030, USD (Million)
- 6.1. Market Overview
- 6.2. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 6.3.Tardive Dyskinesia (TD) Treatment Drugs Market: By Region, 2020-2030, USD (Million)
- 6.3.1.North America
- 6.3.1.1. U.S.
- 6.3.1.1.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 6.3.1.2. Canada
- 6.3.1.2.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 6.3.1.3. Rest of North America
- 6.3.1.3.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 6.3.1.1. U.S.
- 6.3.1.North America
7. UK and European Union Tardive Dyskinesia (TD) Treatment Drugs Market, 2020-2030, USD (Million)
- 7.1. Market Overview
- 7.2. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 7.3.Tardive Dyskinesia (TD) Treatment Drugs Market: By Region, 2020-2030, USD (Million)
- 7.3.1.UK and European Union
- 7.3.1.1. UK
- 7.3.1.1.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 7.3.1.2. Germany
- 7.3.1.2.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 7.3.1.3. Spain
- 7.3.1.3.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 7.3.1.4. Italy
- 7.3.1.4.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 7.3.1.5. France
- 7.3.1.5.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 7.3.1.6. Rest of Europe
- 7.3.1.6.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 7.3.1.1. UK
- 7.3.1.UK and European Union
8. Asia Pacific Tardive Dyskinesia (TD) Treatment Drugs Market, 2020-2030, USD (Million)
- 8.1. Market Overview
- 8.2. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 8.3.Tardive Dyskinesia (TD) Treatment Drugs Market: By Region, 2020-2030, USD (Million)
- 8.3.1.Asia Pacific
- 8.3.1.1. China
- 8.3.1.1.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 8.3.1.2. Japan
- 8.3.1.2.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 8.3.1.3. India
- 8.3.1.3.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 8.3.1.4. Australia
- 8.3.1.4.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 8.3.1.5. South Korea
- 8.3.1.5.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 8.3.1.6. Rest of Asia Pacific
- 8.3.1.6.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 8.3.1.1. China
- 8.3.1.Asia Pacific
9. Latin America Tardive Dyskinesia (TD) Treatment Drugs Market, 2020-2030, USD (Million)
- 9.1. Market Overview
- 9.2. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 9.3.Tardive Dyskinesia (TD) Treatment Drugs Market: By Region, 2020-2030, USD (Million)
- 9.3.1.Latin America
- 9.3.1.1. Brazil
- 9.3.1.1.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 9.3.1.2. Mexico
- 9.3.1.2.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 9.3.1.3. Rest of Latin America
- 9.3.1.3.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 9.3.1.1. Brazil
- 9.3.1.Latin America
10. Middle East and Africa Tardive Dyskinesia (TD) Treatment Drugs Market, 2020-2030, USD (Million)
- 10.1. Market Overview
- 10.2. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 10.3.Tardive Dyskinesia (TD) Treatment Drugs Market: By Region, 2020-2030, USD (Million)
- 10.3.1.Middle East and Africa
- 10.3.1.1. GCC
- 10.3.1.1.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 10.3.1.2. Africa
- 10.3.1.2.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 10.3.1.3. Rest of Middle East and Africa
- 10.3.1.3.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
- 10.3.1.1. GCC
- 10.3.1.Middle East and Africa
11. Company Profile
- 11.1. Auspex Pharmaceuticals
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Portfolio
- 11.1.4. Strategic Initiatives
- 11.2. Neurocrine Biosciences, Inc.
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Portfolio
- 11.2.4. Strategic Initiatives
- 11.3. Synchroneuron Inc.
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Portfolio
- 11.3.4. Strategic Initiatives
- 11.4. Teva Pharmaceutical Industries Ltd.
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Portfolio
- 11.4.4. Strategic Initiatives
- 11.5. Other Notable Players
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Portfolio
- 11.5.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 2 North America Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 3 U.S. Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 4 Canada Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 5 Rest of North America Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 6 UK and European Union Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 7 UK Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 8 Germany Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 9 Spain Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 10 Italy Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 11 France Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 12 Rest of Europe Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 13 Asia Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 14 China Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 15 Japan Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 16 India Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 17 Australia Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 18 South Korea Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 19 Latin America Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 20 Brazil Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 21 Mexico Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 22 Rest of Latin America Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 23 Middle East and Africa Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 24 GCC Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 25 Africa Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
- TABLE 26 Rest of Middle East and Africa Tardive Dyskinesia (TD) Treatment Drugs Market By Drug, 2020-2030, USD (Million)
List of Figures
- FIG. 1 Global Tardive Dyskinesia (TD) Treatment Drugs Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Tardive Dyskinesia (TD) Treatment Drugs Market: Quality Assurance
- FIG. 5 Global Tardive Dyskinesia (TD) Treatment Drugs Market, By Drug, 2021
- FIG. 6 Global Tardive Dyskinesia (TD) Treatment Drugs Market, By Geography, 2021
- FIG. 7 Market Geographical Opportunity Matrix - Global Tardive Dyskinesia (TD) Treatment Drugs Market, 2021
- FIG. 8 Market Positioning of Key Tardive Dyskinesia (TD) Treatment Drugs Market Players, 2021
- FIG. 9 Global Tardive Dyskinesia (TD) Treatment Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
- FIG. 10 Global Tardive Dyskinesia (TD) Treatment Drugs Market, By Drug, 2021 Vs 2030, %
- FIG. 11 U.S. Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 12 Canada Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 13 Rest of North America Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 14 UK Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 15 Germany Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 16 Spain Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 17 Italy Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 18 France Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 19 Rest of Europe Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 20 China Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 21 Japan Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 22 India Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 23 Australia Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 24 South Korea Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 25 Rest of Asia Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 26 Brazil Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 27 Mexico Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 28 Rest of Latin America Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 29 GCC Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 30 Africa Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
- FIG. 31 Rest of Middle East and Africa Tardive Dyskinesia (TD) Treatment Drugs Market (US$ Million), 2020 - 2030
